Lexeo Therapeutics, Inc. Common Stock (LXEO)
Healthcare
Biotechnology
—
4.10 $
-5.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Lexeo Therapeutics, Inc. Common Stock (LXEO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 60.3% of the shares are freely tradable; institutional investors hold 115.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
115.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
60.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
21.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
79Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 7.88 | 6,184,134 | +29.8 | 03/31/2026 |
| BlackRock Inc | 6.51 | 5,110,871 | +4.1 | 03/31/2026 |
| Affinity Asset Advisors, LLC | 6.43 | 5,050,211 | +57.8 | 03/31/2026 |
| RA Capital Management, LLC | 6.37 | 5,000,000 | +0.0 | 03/31/2026 |
| HHG PLC | 6.34 | 4,976,429 | -9.7 | 03/31/2026 |
| Vestal Point Capital LP | 5.70 | 4,475,000 | +0.0 | 03/31/2026 |
| Frazier Life Sciences Management, L.P. | 5.64 | 4,424,725 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.96 | 3,894,310 | +74.9 | 12/31/2025 |
| Citadel Advisors Llc | 4.88 | 3,834,999 | +1.6 | 03/31/2026 |
| Orbimed Advisors, LLC | 4.59 | 3,602,450 | +69.5 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.